Table 1.
A comprehensive list of therapeutic drugs targeting HNF4α activity in cancer.
| Cancer type | Mechanism of drug action | References | |
|---|---|---|---|
| Gene therapy (delivery of LETF) | Liver cancer | Induces MET and epithelial/hepatic differentiation and blocks EMT carcinogenesis and metastasis | 93 |
| Oroxylin A | Liver cancer | Activates the PKM1/HNF4α pathway | 95 |
| 5-Aza-Cd | Liver cancer | Induces PPARγ/RXRα and restores miR-122 expression | 96 |
| BI6015 | Gastric cancer | Suppresses the Wnt and Notch embryonic signaling pathways | 97 |
| Berberine | Gastric cancer | Is involved in the AMPK-HNF4α-WNT5A signaling pathway | 98 |
| HDAC inhibitors | Colon carcinoma | Downregulates MUC4 | 99 |
| Dasatinib, AZD-0530 and SKI-606 | Colorectal cancer | Increases P1-HNF4α protein levels and suppresses colon cancer progression | 13 |
| Oxaliplatin and 5-FU | Renal cell carcinoma | Overexpression of HNF4α induces chemosensitivity to oxaliplatin and 5-FU mediated by OCT1 and CNT3 | 53 |
| Apicidin (histone deacetylase inhibitor) | Pancreatic cancer | Reduces the expression of MUC4 and its transcription factor HNF4α | 100 |
| miR-34a | Neuroblastoma | Targets HNF4α to inhibit proliferation, migration and invasion | 57 |